Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects With Early Alzheimer's Disease (AD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jul 2023
Price :
$35
*
At a glance
- Drugs Buntanetap (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms DISCOVER
- Sponsors Annovis Bio
- 18 Jul 2023 According to an Annovis Bio media release, data from this trial was presented in a posters presentation by Don Elbert, Ph.D., at the Alzheimer's Association International Conference (AAIC) 2023 annual meeting held in Amsterdam, Netherlands, from July 16 - 20.
- 11 May 2023 According to an Annovis Bio media release, data from this study was presented at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases.
- 11 May 2023 Status changed from active, no longer recruiting to completed.